Stimulation by epigallocatechin gallate of interleukin-1 production by human peripheral blood mononuclear cells. 1995

H Sakagami, and M Takeda, and K Sugaya, and T Omata, and H Takahashi, and M Yamamura, and Y Hara, and T Shimamura
First Department of Biochemistry, School of Medicine, Showa University, Tokyo, Japan.

(-) Epigallocatechin gallate (EGCg) potently stimulated the production of interleukin-1 (IL-1) and tumor necrosis factor by human peripheral blood mononuclear cells. The intracellular amounts of IL-1 beta and especially IL-1 alpha induced by EGCg, were significantly higher than their extracellular counterparts. ECCg stimulated the production of adherent cells, with IL-1 producing capacity (per cell basis) that was significantly higher than nonadherent cells. Although IL-1 alpha mRNA synthesis (assessed by Reverse Transcriptase-Polymerase Chain Reaction) was slightly enhanced, IL-1 beta mRNA synthesis was not significantly enhanced by EGCg treatment. Lipopolysaccharide (LPS) also stimulated the production of IL-1 alpha and IL-1 beta production, but failed to induce the adherent cells. These data suggest that EGCg and LPS stimulate mononuclear cells by different mechanisms.

UI MeSH Term Description Entries
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D002392 Catechin An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms. Catechinic Acid,Catechuic Acid,(+)-Catechin,(+)-Cyanidanol,(+)-Cyanidanol-3,(-)-Epicatechin,(2R,3R)-2-(3,4-Dihydroxyphenyl)-3,5,7-chromanetriol,2H-1-Benzopyran-3,5,7-triol, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-, (2R-cis)-,3,3',4',5,7-Flavanpentol,Catergen,Cianidanol,Cyanidanol-3,Epicatechin,KB-53,Z 7300,Zyma,Cyanidanol 3,KB 53,KB53
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated

Related Publications

H Sakagami, and M Takeda, and K Sugaya, and T Omata, and H Takahashi, and M Yamamura, and Y Hara, and T Shimamura
May 1992, Journal of leukocyte biology,
H Sakagami, and M Takeda, and K Sugaya, and T Omata, and H Takahashi, and M Yamamura, and Y Hara, and T Shimamura
June 1990, Molecular and cellular biochemistry,
H Sakagami, and M Takeda, and K Sugaya, and T Omata, and H Takahashi, and M Yamamura, and Y Hara, and T Shimamura
September 1984, Infection and immunity,
H Sakagami, and M Takeda, and K Sugaya, and T Omata, and H Takahashi, and M Yamamura, and Y Hara, and T Shimamura
September 1993, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association,
H Sakagami, and M Takeda, and K Sugaya, and T Omata, and H Takahashi, and M Yamamura, and Y Hara, and T Shimamura
July 1998, AIDS research and human retroviruses,
H Sakagami, and M Takeda, and K Sugaya, and T Omata, and H Takahashi, and M Yamamura, and Y Hara, and T Shimamura
May 1990, Journal of leukocyte biology,
H Sakagami, and M Takeda, and K Sugaya, and T Omata, and H Takahashi, and M Yamamura, and Y Hara, and T Shimamura
May 1988, Journal of the neurological sciences,
H Sakagami, and M Takeda, and K Sugaya, and T Omata, and H Takahashi, and M Yamamura, and Y Hara, and T Shimamura
September 2001, The Journal of infectious diseases,
H Sakagami, and M Takeda, and K Sugaya, and T Omata, and H Takahashi, and M Yamamura, and Y Hara, and T Shimamura
July 1989, Israel journal of medical sciences,
H Sakagami, and M Takeda, and K Sugaya, and T Omata, and H Takahashi, and M Yamamura, and Y Hara, and T Shimamura
September 2005, Clinical immunology (Orlando, Fla.),
Copied contents to your clipboard!